Hydroxychloroquine — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Rheumatoid Arthritis

• Leflunomide
• Methotrexate
• Prednisone
• Sulfasalazine

About Hydroxychloroquine

Hydroxychloroquine is a vital medication for many, primarily used to manage certain autoimmune diseases and prevent malaria. Understanding its role and how to access it affordably is key. TheDrugClub is proud to help members save significantly, often reducing their out-of-pocket costs to $0 for this important prescription, making health more accessible.

Hydroxychloroquine, often recognized by its brand name Plaquenil, is an antimalarial drug that has found extensive use in treating various autoimmune conditions. Its primary applications include managing rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and chronic discoid lupus erythematosus. It can also be prescribed for malaria prevention and treatment in certain situations, making it a versatile medication in the medical arsenal.

So, how does this medication work its magic? While the exact mechanism isn't fully understood, hydroxychloroquine is believed to modulate the immune system. In autoimmune diseases, where the body's immune system mistakenly attacks its own tissues, hydroxychloroquine helps to dampen this overactive response. It reduces inflammation, pain, and swelling, leading to improved symptoms and quality of life for patients. It doesn't work instantly; benefits typically become noticeable after several weeks or even months of consistent use, requiring patience and adherence.

The cost of prescription medications can be a significant burden, and hydroxychloroquine is no exception. Without insurance or with high deductibles, the retail price for a month's supply can vary widely, sometimes reaching hundreds of dollars depending on the pharmacy, dosage, and whether you're purchasing a generic or brand-name version. This financial strain can make adherence difficult, impacting treatment outcomes and overall well-being for many individuals.

This is where TheDrugClub steps in to make a real difference for its members. As a member, you can access your hydroxychloroquine prescription for a *guaranteed $0 co-pay*. That's right – zero dollars out of your pocket for a medication that's crucial for your health management. Beyond the incredible savings, we also understand the importance of convenience and privacy. That's why TheDrugClub members also enjoy *free home delivery* of their hydroxy

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Hydroxychloroquine is approved for (FDA label)

Hydroxychloroquine sulfate is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. ( 1.1 ) Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. ( 1.1 ) Treatment of rheumatoid arthritis in adults. ( 1.2 ) Treatment of systemic lupus erythematosus in adults. ( 1.3 ) Treatment of chronic discoid lupus erythematosus in adults. ( 1.4 ) Limitations of Use ( 1.1 ): Hydroxychloroquine sulfate is not recommended for the: Treatment of complicated malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species.

Source: Read the full FDA label on DailyMed. Label effective date: December 10, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Hydroxychloroquine (FDA label)

Hydroxychloroquine sulfate tablets, USP are white to off white, film coated oval shaped tablets, debossed with “CE” on one side and “173” on other side. Tablets: 200 mg of hydroxychloroquine sulfate ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7e09aeca-0cec-4a88-9dde-a2098a08b877. SPL document ID: 459cd828-6e8f-c7cf-e063-6394a90a5ab8. Label effective date: December 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Hydroxychloroquine (FDA label)

The following adverse reactions are described in greater detail in other sections: Cardiomyopathy and Ventricular Arrhythmias [see Warnings and Precautions (5.1) ] Retinal Toxicity [see Warnings and Precautions (5.2) ] Serious Skin Reactions [see Warnings and Precautions (5.3) ] Worsening of Psoriasis [see Warnings and Precautions (5.4) ] Risks Associated with Use in Porphyria [see Warnings and Precautions (5.5) ] Hematologic Toxicity [see Warnings and Precautions (5.6) ] Hemolytic Anemia Associated with G6PD [see Warnings and Precautions (5.7) ] Skeletal Muscle Myopathy or Neuropathy [see Warnings and Precautions (5.8) ] Neuropsychiatric Reactions Including Suicidality [see Warnings and Precautions (5.9) ] Hypoglycemia [see Warnings and Precautions (5.10) ] Renal Toxicity [see Warnings and Precautions (5.11) ] The following adverse reactions have been identified during post-approval use of 4- aminoquinoline drugs, including hydroxychloroquine sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: - Blood and lymphatic system disorders : Bone marrow depression, anemia, aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia - Cardiac disorders: Cardiomyopathy, cardiac failure, QT interval prolongation, ventricular tachycardia, torsades de pointes, atrioventricular block, bundle branch block, sick sinus syndrome, pulmonary hypertension - Ear and labyrinth disorders: Vertigo, tinnitus, nystagmus, sensorineural hearing loss - Eye disorders: Retinopathy, retinal pigmentation changes (typically bull’s eye appearance), visual field defects (paracentral scotomas), macular degeneration, corneal edema, corneal opacities, decreased dark adaptation - Gastrointestinal disorders: Nausea, vomiting, diarrhea, abdominal pain - General disorders: Fatigue - Hepatobiliary disorders: Abnormal liver function tests, fulminant hepatic failure - Immune system disorders: Urticaria, angioedema, bronchospasm - Metabolism and nutrition disorders: Anorexia, hypoglycemia, weight loss - Musculoskeletal and connective tissue disorders: Proximal myopathy, depressed tendon reflexes, abnormal nerve conduction - Nervous system disorders: Ataxia, dizziness, headache, seizure, extrapyramidal disorders (dystonia, dyskinesia, tremor) - Neuropsychiatric disorders: Affect/emotional lability, irritability, nervousness, psychosis, suicidal ideation, suicidal behavior, depression, hallucinations, anxiety, agitation, confusion, delusions, paranoia, mania and sleep disorders (insomnia, night terrors, nightmares) - Skin and subcutaneous tissue disorders: Alopecia, hair color changes, rash, pruritus, photosensitivity, psoriasis exacerbation, hyperpigmentation, exfoliative dermatitis, erythema multiforme, acute generalized exanthematous pustulosis, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) The most common adverse reactions reported are: nausea, vomiting, diarrhea, and abdominal pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Source: FDA prescribing information (DailyMed). Set ID: 7e09aeca-0cec-4a88-9dde-a2098a08b877. SPL document ID: 459cd828-6e8f-c7cf-e063-6394a90a5ab8. Label effective date: December 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Hydroxychloroquine (FDA label)

hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4- aminoquinoline compounds. Patients with hypersensitivity to 4-aminoquinoline compounds ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 7e09aeca-0cec-4a88-9dde-a2098a08b877. SPL document ID: 459cd828-6e8f-c7cf-e063-6394a90a5ab8. Label effective date: December 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Hydroxychloroquine (FDA label)

Cardiomyopathy and Ventricular Arrhythmias: Fatal or life-threatening cardiomyopathy and ventricular arrhythmias were reported. ( 5.1 ) Retinal Toxicity: Irreversible retinal damage is related to cumulative dosage and treatment duration. Baseline retinal exam and exams during treatment are recommended. ( 5.2 ) Serious Skin Reactions: Stevens Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis have been reported. ( 5.3 ) Worsening of Psoriasis: Avoid in patients with psoriasis. ( 5.4 ) Risks Associated with Use in Porphyria: Avoid in patients with porphyria. Hepatotoxicity was reported in patients with porphyria cutanea tarda ( 5.5 ). Hematologic Toxicity: Discontinue if myelosuppression occurs. ( 5.6 ) Renal Toxicity: Consider phospholipidosis as a possible cause of renal injury in patients with underlying connective tissue disorders.

Source: FDA prescribing information (DailyMed). Set ID: 7e09aeca-0cec-4a88-9dde-a2098a08b877. SPL document ID: 459cd828-6e8f-c7cf-e063-6394a90a5ab8. Label effective date: December 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Hydroxychloroquine (FDA label)

Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7.1 ) See FPI for more important drug interactions. ( 7 ) 7.1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic [see Warnings and Precautions (5.1) ]. 7.2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary [see Warnings and Precautions (5.10) ]. 7.3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seizure threshold.

Source: FDA prescribing information (DailyMed). Set ID: 7e09aeca-0cec-4a88-9dde-a2098a08b877. SPL document ID: 459cd828-6e8f-c7cf-e063-6394a90a5ab8. Label effective date: December 10, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.